{
    "code": "02025791",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025791",
    "time": "2019-11-29 03:08:04",
    "許可證字號": "衛署藥輸字第025791號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/08\/10",
    "發證日期": "101\/08\/10",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202579109",
    "中文品名": "托普迪肯 &quot;山德士&quot; 1毫克\/毫升注射劑",
    "英文品名": "Topotecan Sandoz 1mg\/ml Concentrate for Solution for Infusion",
    "適應症": "Topotecan 用於治療卵巢癌及小細胞肺癌之第二線化學治療(第一線化療應包括白金化合物)。Topotecan 與 cisplatin 併用適用於治療經組織學檢查確定患有第IV-B期復發性或持續性子宮頸癌，且不適合以外科手術及(或)放射療法進行治療的患者。",
    "劑型": "270注射劑",
    "包裝": "1, 3, 4毫升小瓶裝 100支以下盒裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入",
        "申請商名稱": "1422701100  台灣諾華股份有限公司",
        "申請商地址": "台北市中山區民生東路三段2號8樓",
        "主製造廠": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000310",
            "成分名稱": "TOPOTECAN HYDROCHLORIDE",
            "含量描述": "(corresponding to 1mg Topotecan)",
            "含量": "1.0865000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Label-104-09-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Topotecan PI_TWI-130716 (final)-106-04-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=005&Type=9"
        },
        {
            "title": "1.3.4.1 SKE (Entwurf .pdf), , 46132575-01, 2-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=019&Type=8"
        },
        {
            "title": "1.3.4.1 SKE (Entwurf .pdf), , 46132573-01, 2-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=018&Type=8"
        },
        {
            "title": "1.3.4.1 SKE (Entwurf .pdf), , 46132437-01, 3-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=017&Type=8"
        },
        {
            "title": "1.1.4.1 FS (Entwurf .pdf), , 46132576-01, 2-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=016&Type=8"
        },
        {
            "title": "1.1.4.1 FS (Entwurf .pdf), , 46132574-01, 2-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=015&Type=8"
        },
        {
            "title": "1.1.4.1 FS (Entwurf .pdf), , 46132439-01, 2-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025791&Seq=014&Type=8"
        }
    ]
}